Campbell & CO Investment Adviser LLC Ultragenyx Pharmaceutical Inc. Transaction History

Campbell & CO Investment Adviser LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$37.42 - $51.61 $1.27 Million - $1.75 Million	33,868 New	33,868 $1.39 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $403,036 - $667,088	10,086 New	10,086 $418,000
Q2 2022 Aug 09, 2022	SELL	$45.8 - $85.4 $347,164 - $647,332	-7,580 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$62.2 - $84.4 $228,896 - $310,592	3,680 Added 94.36%	7,580 $550,000
Q4 2021 Feb 10, 2022	BUY	$73.71 - $87.86 $47,911 - $57,109	650 Added 20.0%	3,900 $328,000
Q3 2021 Nov 10, 2021	BUY	$77.92 - $102.4 $54,544 - $71,680	700 Added 27.45%	3,250 $293,000
Q2 2021 Aug 11, 2021	SELL	$92.19 - $115.71 $96,799 - $121,495	-1,050 Reduced 29.17%	2,550 $243,000
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $384,840 - $603,828	3,600 New	3,600 $410,000
Q4 2019 Jan 23, 2020	SELL	$36.08 - $45.83 $477,843 - $606,972	-13,244 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$42.5 - $63.11 $562,870 - $835,828	13,244 New	13,244 $567,000
Q1 2019 May 10, 2019	SELL	$39.87 - $69.36 $350,457 - $609,674	-8,790 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$38.89 - $77.3 $341,843 - $679,467	8,790 New	8,790 $423,000

329

85.9M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.18B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.